| Aug 15 |
Incyte Announces Positive Topline Results from Pivotal Study of Tafasitamab (Monjuvi®) in Relapsed or Refractory Follicular Lymphoma
|
| Aug 15 |
FDA greenlights Incyte and Syndax’s GvHD drug Niktimvo
|
| Aug 15 |
FDA Approves Incyte/Syndax Partnered Drug For Chronic Graft-Versus-Host Disease, A Post-Transplant Complication
|
| Aug 15 |
Incyte builds out its arsenal of post-transplant drugs
|
| Aug 14 |
Incyte and Syndax Announce U.S. FDA Approval of Niktimvo™ (axatilimab-csfr) for the Treatment of Chronic Graft-Versus-Host Disease (GVHD)
|
| Aug 14 |
FDA approves Incyte's Niktimvo for chronic graft-versus-host disease
|
| Aug 14 |
Do Options Traders Know Something About Incyte (INCY) Stock We Don't?
|
| Aug 13 |
Incyte to Present at Upcoming Investor Conferences
|
| Aug 7 |
Incyte's (NASDAQ:INCY) Weak Earnings May Only Reveal A Part Of The Whole Picture
|
| Aug 1 |
Incyte Second Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags
|
